15 Stocks with Buy Ratings that Hedge Funds Love

Page 8 of 13

6. Natera, Inc. (NASDAQ:NTRA)

No. of Hedge Funds: 77

Value of the hedge funds: $4.29 billion

Based in Austin, Texas, Natera, Inc. (NASDAQ:NTRA), a genetic testing company, offers screening solutions for oncology, women’s health (including prenatal testing), and organ health monitoring. The company’s focus is particularly on cell-free DNA technology for non-invasive diagnostics. Serving hospitals, physicians, and research institutions, the company competes with Guardant Health and Invitae for market share. Natera’s proprietary algorithm (SIGNAL) and clinical validation across multiple applications provide a competitive edge. It is among the stocks with Buy ratings.

Natera, Inc. (NASDAQ:NTRA)’s has caught the eye of 77 hedge funds, accumulating $4.29 billion in positions and reflecting high institutional interest. Reaching $476 million in revenue, a 53% year-on-year growth, Natera has surpassed its pre-announcement. The company expanded its market reach by achieving Medicare coverage for Signatera in non-small cell lung cancer. It has also increased the potential revenue stream for the company in 2025. Natera has also announced that it is employing its AI capabilities in the reimbursement process, which results in optimized financial performance. For 2025, the company targets a revenue of $1.87 billion to $1.95 billion 2025.

Despite a modest 3.18% EPS growth over five years, analysts maintain a Strong Buy rating for Natera, Inc. (NASDAQ:NTRA) since the expectations regarding the genomic technology’s future impact are high.

Page 8 of 13